Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations

February 26, 2021

Originally Posted in medRxiv

July 29, 2020

Abstract: Multiple clinical studies are ongoing to assess whether existing vaccines may afford protection against SARS-CoV-2 infection through trained immunity. In this exploratory study, we analyze immunization records from 137,037 individuals who received SARS-CoV-2 PCR tests. We find that polio, Hemophilus influenzae type-B (HIB), measles-mumps-rubella (MMR), varicella, pneumococcal conjugate (PCV13), geriatric flu, and hepatitis A / hepatitis B (HepA-HepB) vaccines administered in the past 1, 2, and 5 years are associated with decreased SARS-CoV-2 infection rates, even after adjusting for geographic SARS-CoV-2 incidence and testing rates, demographics, comorbidities, and number of other vaccinations. Furthermore, age, race/ethnicity, and blood group stratified analyses reveal significantly lower SARS-CoV-2 rate among black individuals who have taken the PCV13 vaccine, with relative risk of 0.45 at the 5 year time horizon (n: 653, 95% CI: (0.32, 0.64), p-value: 6.9e-05). These findings suggest that additional pre-clinical and clinical studies are warranted to assess the protective effects of existing non-COVID-19 vaccines and explore underlying immunologic mechanisms. We note that the findings in this study are preliminary and are subject to change as more data becomes available and as further analysis is conducted.

 

Authors:

Colin PawlowskiArjun PuranikHari BandiAJ VenkatakrishnanVineet Agarwal, Richard KennedyJohn C. O’HoroGregory J. Gores, Amy W. Williams, John HalamkaAndrew D. Badley, Venky Soundararajan

nference, Cambridge, MA 02142, USA
Mayo Clinic, Rochester, MN 55905, USA
 
 
Correspondence: Venky Soundararajan (venky@nference.net)

 

NewYorkTimes  

 

Affiliations:

nference-logo

mayo-logo-3-3-Mar-05-2021-08-48-39-00-PM

Copyright:
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.